Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

BIAL launches ONGENTYS® (opicapone) a novel treatment for Parkinson´s disease patients with motor fluctuations in the UK

Posted on: 17 Oct 16

Porto, 17 October 2016 - ONGENTYS® (opicapone) has now been launched in the UK for the treatment of adult Parkinson´s disease patients with motor fluctuations.


ONGENTYS® (opicapone) was authorised by the European Commission in June 2016 as an adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.


Several therapeutic strategies are available to improve the signs and symptoms of Parkinson´s disease, mainly dopaminergic drugs avoiding the degradation or mimicking dopamine physiological effects. Levodopa remains the gold-standard treatment for the disease, although its long-term use causes what is known as motor complications, like end of dose motor complications or wearing-off. "Wearing-off" episodes may be improved with appropriate changes in the medication regimen, i.e. adding an extra dose of levodopa or using a COMT inhibitor.


“There is still an unmet medical need for effective new therapeutic options for Parkinson´s disease. Opicapone will provide clinicians in UK with a COMT inhibitor, with the convenience of once-daily dosing. It is an option when levodopa-treated patients need additional help to improve motor symptoms such as wearing off in Parkinson´s disease.”, said Professor Andrew Lees, Professor of Neurology at the National Hospital for Neurology and Neurosurgery, Queen Square, London and University College London.


“Studies have shown that ONGENTYS® (opicapone) is an effective, once-daily, an adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations. We are pleased that opicapone is now available in UK, a country where BIAL has recently opened an affiliate. Opicapone is the outcome of BIAL’s longstanding scientific commitment to neurological research. These launches also reflect BIAL’s increasing European footprint and the company’s mission to care for the Health of people worldwide”, comments António Portela, CEO of BIAL.


The European Commission authorisation for opicapone was based on data from a clinical development programme which included 28 human pharmacology studies with more than 900 patients exposed to opicapone in 30 countries worldwide. The two pivotal phase III studies, BIPARK-I2 and BIPARK-II3 demonstrated that opicapone once-daily achieved an absolute reduction in OFF-time of 103 and 107 minutes respectively and statistically significant increases in ON-time without troublesome dyskinesia compared to placebo (P=0.002).


Opicapone was also associated with significant improvements in both patient and clinician global assessments of change. BIPARK-I was an active-controlled trial and included an entacapone arm: opicapone once-daily demonstrated to be non-inferior to entacapone dosed multiple times per day. The data from the phase III trials demonstrated that opicapone improves motor fluctuations in levodopa-treated patients regardless of concomitant dopamine agonist or monoamine oxidase type B inhibitors use4. It has also been demonstrated to have a generally favourable safety and tolerability profile in the whole trial population and in the subset of patients over 70 years, and is not associated with relevant electrocardiographic or hepatic adverse events.


Both phase III trials included a 1-year open-label extension and opicapone demonstrated an OFF-time reduction from the double-blind phase baseline that was sustained over the open-label phase


BIAL anticipates additional EU launches of opicapone over the coming year. The company recently opened affiliates in Frankfurt and London, so as to strengthen its internationalisation strategy and the commercialisation of its medicines in those countries.


Parkinson's disease is a neurodegenerative, chronic and progressive disease. The clinical manifestations usually start after the age of 50 years (average age for diagnosis is approximately 60 years) and the prevalence is estimated at 300 per 100,000 inhabitants, increasing to 1/100 over the age of 55–60 years. According to the European Parkinson’s Disease Association (EPDA) around 6.3 million people have Parkinson’s worldwide. Along with available statistics, 1.2 million people in the European Union have Parkinson’s, approximately 260,000 in Germany and 120,000 in UK.


Editor's Details

Mike Wood

Last updated on: 17/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.